Oracle Corporation (NYSE: ORCL) has been named a Leader in the IDC MarketScape: Worldwide Life Sciences R&D RWD/RWE for Data Platforms, Technology Solutions, and Consulting Services 2026 Vendor Assessment.
The IDC MarketScape highlights Oracle’s “long legacy for providing RWD/RWE solutions to strengthen its customers’ regulatory submissions strategy, enhance their market access and reimbursement strategies, and optimize their success for product commercialization.”
The report notes that Oracle has delivered real-world data and real-world evidence solutions for over 40 years, aggregating real-world electronic health record data for nearly two decades through its health system network.
Oracle launched an RWD platform following its 2022 acquisition of Cerner, and followed that with a next-generation AI-powered life sciences platform in 2026, with the company reported to work with every major pharma organization.
Dr. Nimita Limaye, research vice president of Life Sciences R&D Strategy and Technology at IDC, offered a direct assessment of Oracle’s standing in the space.
“Oracle brings together real-world data, technology, and scientific and regulatory expertise within an integrated offering that can support organizations across multiple stages of the research lifecycle,” said Dr. Limaye.
Dr. Limaye added that “Oracle is uniquely equipped to help life sciences organizations maximize the value and scale of their real-world evidence,” citing the company’s continued investment in AI-enabled capabilities.
Oracle Life Sciences Data Intelligence integrates customer-supplied data with Oracle Health Real-World Data, which consists of more than 122 million de-identified, representative patient records generated through the Oracle Learning Health Network.
That network spans more than 255 health systems, providing a foundation for clinical research, regulatory evidence generation, market access, and commercialization initiatives across the life sciences sector.
The IDC report also noted that Oracle offers “out-of-the-box and customizable AI agents supporting natural language querying, cohort identification, synthetic control arm generation, health economics and outcomes research, safety signal detection, and regulatory submission support.”
Seema Verma, executive vice president and general manager of Oracle Health and Life Sciences, pointed to the company’s domain expertise as central to its competitive position.
“Our deep domain expertise, combined with significant investments in AI and real-world data, can help life sciences organizations make more informed decisions,” said Verma.
Verma added that the company believes “this recognition from IDC MarketScape reflects our experience in real-world evidence and our commitment to helping life sciences organizations turn data into insights that can advance the development of new treatments.”
The recognition coincides with the Oracle Health and Life Sciences Summit, taking place September 22 through 24, 2026, in Orlando, Florida, where the company is expected to showcase its expanding portfolio of health and life sciences solutions.
